Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinically relevant gene editing in hematopoietic stem cells for the treatment of pyruvate kinase deficiency.
Fañanas-Baquero S, Quintana-Bustamante O, Dever DP, Alberquilla O, Sanchez-Dominguez R, Camarena J, Ojeda-Perez I, Dessy-Rodriguez M, Turk R, Schubert MS, Lattanzi A, Xu L, Lopez-Lorenzo JL, Bianchi P, Bueren JA, Behlke MA, Porteus M, Segovia JC. Fañanas-Baquero S, et al. Mol Ther Methods Clin Dev. 2021 May 14;22:237-248. doi: 10.1016/j.omtm.2021.05.001. eCollection 2021 Sep 10. Mol Ther Methods Clin Dev. 2021. PMID: 34485608 Free PMC article.
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
Simoes C, Villar S, Ariceta B, Garcés JJ, Burgos L, Alignani D, Sarvide S, Martínez-Cuadrón D, Bergua JM, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lopez-Lorenzo JL, Vidriales MB, Chillon C, Labrador J, Falantes JF, Sayas MJ, Ayala R, Martinez-Lopez J, Pierola AA, Calasanz MJ, Prosper F, San-Miguel JF, Sanz MÁ, Paiva B, Montesinos P; PETHEMA cooperative study group. Simoes C, et al. Br J Haematol. 2023 Jun;201(6):1239-1244. doi: 10.1111/bjh.18815. Epub 2023 Apr 14. Br J Haematol. 2023. PMID: 37057357 No abstract available.
Who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency (PKD)?: Toward an expanded definition of severe PKD.
Schwartz JD, Barcellini W, Grace RF, Bianchi P, Zanella A, López Lorenzo JL, Sevilla J, Shah AJ, Glader B, Nicoletti E, Navarro Ordoñez S, Segovia JC. Schwartz JD, et al. Am J Hematol. 2022 Mar 1;97(3):E120-E125. doi: 10.1002/ajh.26458. Epub 2022 Jan 24. Am J Hematol. 2022. PMID: 34989415 Free PMC article. Review. No abstract available.
Exploiting the passenger ACO1-deficiency arising from 9p21 deletions to kill T-cell lymphoblastic neoplasia cells.
Gonzalez-Sanchez L, Cobos-Fernandez MA, Lopez-Nieva P, Villa-Morales M, Stamatakis K, Cuezva JM, Marin-Rubio JL, Vazquez-Dominguez I, Gonzalez-Vasconcellos I, Salido E, Llamas P, Lopez-Lorenzo JL, Santos J, Fernandez-Piqueras J. Gonzalez-Sanchez L, et al. Carcinogenesis. 2020 Aug 12;41(8):1113-1122. doi: 10.1093/carcin/bgz185. Carcinogenesis. 2020. PMID: 31734690 Free article.
Comparison of Droplet Digital PCR versus qPCR Measurements on the International Scale for the Molecular Monitoring of Chronic Myeloid Leukemia Patients.
Cortés AA, Olmedillas S, Serrano-López J, Lainez-González D, Castaño T, Iñiguez R, Lopez-Lorenzo JL, García A, Atance M, Sánchez RNS, Lopez CB, Arranz MG, Sillero PL, Alonso-Dominguez JM. Cortés AA, et al. Mol Diagn Ther. 2020 Oct;24(5):593-600. doi: 10.1007/s40291-020-00485-4. Mol Diagn Ther. 2020. PMID: 32875515
Downregulation of specific FBXW7 isoforms with differential effects in T-cell lymphoblastic lymphoma.
Vázquez-Domínguez I, González-Sánchez L, López-Nieva P, Fernández-Navarro P, Villa-Morales M, Cobos-Fernández MÁ, Sastre I, F Fraga M, F Fernández A, Malumbres M, Salazar-Roa M, Graña-Castro O, Santos J, Llamas P, López-Lorenzo JL, Fernández-Piqueras J. Vázquez-Domínguez I, et al. Oncogene. 2019 Jun;38(23):4620-4636. doi: 10.1038/s41388-019-0746-1. Epub 2019 Feb 11. Oncogene. 2019. PMID: 30742097
Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program.
García-Gutiérrez V, Martinez-Trillos A, Lopez Lorenzo JL, Bautista G, Martin Mateos ML, Alvarez-Larrán A, Iglesias Pérez A, Romo Collado A, Fernandez A, Portero A, Cuevas B, Ruiz C, Romero E, Ortega F, Mata I, Tallón J, García Garay Mdel C, Ramirez Sánchez MJ, de Las Heras N, Giraldo P, Bobillo S, Guinea JM, Deben G, Valencia S, Sebrango A, Boqué C, Maestro B, Steegmann JL. García-Gutiérrez V, et al. Am J Hematol. 2015 May;90(5):429-33. doi: 10.1002/ajh.23973. Epub 2015 Mar 30. Am J Hematol. 2015. PMID: 25683327 Free article.
An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.
Steegmann JL, Colomer D, Gómez-Casares MT, García-Gutiérrez V, Ortí G, Ramírez-Payer A, Olavarria E, Vall-Llovera F, Giraldo P, Conde E, Vallansot R, López-Lorenzo JL, Palomera L, Álvarez-Larrán A, Conesa V, Bautista G, Casas L, Giles F, Hochhaus A, Casado-Montero LF. Steegmann JL, et al. J Cancer Res Clin Oncol. 2017 Oct;143(10):2059-2066. doi: 10.1007/s00432-017-2445-z. Epub 2017 May 27. J Cancer Res Clin Oncol. 2017. PMID: 28551768 Free PMC article.
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.
Hernández-Boluda JC, Pereira A, Pastor-Galán I, Alvarez-Larrán A, Savchuk A, Puerta JM, Sánchez-Pina JM, Collado R, Díaz-González A, Angona A, Sagüés M, García-Gutiérrez V, Boqué C, Osorio S, Vallansot R, Palomera L, Mendizábal A, Casado LF, Pérez-Encinas M, Pérez-López R, Ferrer-Marín F, Sánchez-Guijo F, García C, Heras NL, López-Lorenzo JL, Cervantes F, Steegmann JL; Grupo Español de Leucemia Mieloide Crónica (GELMC). Hernández-Boluda JC, et al. Blood Cancer J. 2018 Dec 2;8(10):91. doi: 10.1038/s41408-018-0125-0. Blood Cancer J. 2018. PMID: 30504932 Free PMC article.
53 results